Life Technologies Corporation
) entered into a global distribution agreement with Advanced Cell
Diagnostics (ACD) to commercialize the latter's fluorescent
RNAscope portfolio of probes and kits in the research market.
Life Technologies will distribute ACD's portfolio through its
widespread global distribution network.
Advanced Cell Diagnostics completed a $12 million Series B equity
financing deal in Nov 2012 to support the commercial expansion of
its unique RNAscope-based products and services in the life
science research market and expedite its entry into the clinical
The new collaboration is expected to open up a largely untapped
market and at the same time, accelerate the development of
On the other hand, LIFE's decision to distribute the RNAscope
portfolio reflects its long-standing commitment to make available
the most innovative products and services to the researchers. It
also marks the entry of the company into the growing tissue
analysis market. The extensive availability of the RNAscope from
ACD is expected to help researchers overcome major technical
hurdles involved in the study of the heterogeneous samples.
RNAscope technology is the first automated multiplex in situ
hybridization platform developed to detect and quantify RNA
biomarkers in situ at single-molecule sensitivity. The technology
provides single-cell gene expression information within full
cellular and tissue context. It also reveals valuable,
morphological information with respect to newly identified
biomarkers in both cells and complex tissues.
RNAscope can work with both routine clinical specimen and
standard clinical laboratory workflow. Such added features will
smoothen the work of researchers by removing the shortcomings
faced due to lack of antibodies, complementing both
next-generation sequencing (NGS) and qPCR methods.
The pioneering technology developed by ACD enables researchers to
visualize and quantify RNA in tissue samples. It can
simultaneously preserve the tissue context and provide
single-molecule RNA detection. Such improvements facilitate
researchers to detect the appropriate biomarker in specific
cells, even when using a traditional fluorescence microscope.
RNAscope is poised to become a winning technique for identifying
and validating RNA biomarkers in tissue for research, molecular
diagnostics and companion diagnostics purposes. A spontaneous
rise in discovery of biomarkers identified from microarray and
NGS technologies is anticipated due to the growing momentum of
cancer and neurobiology research.
Currently, LIFE carries a Zacks Rank #4 (Sell). Other
better-placed medical stocks that are worth a look include
Trinity Biotech plc
), carrying a Zacks Rank #1 (Strong Buy), and
Boston Scientific Corp.
), each carrying a Zacks Rank #2 (Buy).
ADVAXIS INC (ADXS): Free Stock Analysis
BOSTON SCIENTIF (BSX): Free Stock Analysis
LIFE TECHNOLOGS (LIFE): Free Stock Analysis
TRINITY BIOTECH (TRIB): Free Stock Analysis
To read this article on Zacks.com click here.